Dr. Adam Fein PhD
Founder & President, PEMBROKE CONSULTING INC
Member of the Healthcare Council
Council Member Biography
Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country’s foremost experts on pharmacy economics and the pharmaceutical supply chain. He provides strategic advisory services to a diverse mix of clients, including pharmaceutical manufacturers, pharmacy benefit managers, supply chain technology companies, law firms, health care providers, retailers, trade associations, and institutional investors. Dr. Fein has published over 100 academic and industry articles, authored or edited nine books, and currently writes the popular blog DrugChannels.net. He is frequently sought by the media for his industry expertise and has been quoted in many leading national publications. Dr. Fein serves as the first Fellow of the NAW Institute for Distribution Excellence and is on the Advisory Boards of Supply Chain Equity Partners, Secure Symbology, IntegriChain, and Pharmaceutical Commerce magazine. (This is me - Update Profile)
Employment History
- 1997 - Unspecified
- Founder & President, PEMBROKE CONSULTING INC
GLG NewsSM Analyses by Adam Fein(?)
-
No Visible Revenue Synergies in CVS Caremark's Latest Numbers
February 23, 2009
CVS Net Rises; Finance Chief Plans to Retire | online.wsj.com
CVS Caremark’s PBM businesses are not becoming a larger share of prescriptions filled at CVS retail pharmacies. Put another way, the flagship Maintenance Choice program may be appealing to payers and consumers, but there is not yet a quantitatively visible shift in CVS' retail activity. If CVS pharmacies are taking retail pharmacy market share, then it’s not yet as a result of corporate co-ownership with a PBM.
-
January 16, 2009
Health-Care Outlays Climb at Slowest Rate in Years | online.wsj.com
U.S. spending on outpatient prescription drugs grew by only 4.9 percent in 2007, which was below overall health care spending growth of 6.1 percent. Public funds (primarily Medicare and Medicaid) paid for 36 percent of total retail prescription drug spending in 2007. So, how much money do pharmacies make from Medicare and Medicaid? The answers may surprise you. Here’s what I found: (1) Medicaid remains the most profitable third-party payer for independent pharmacies. (2) Despite what you may have heard, gross margins on third-party insurance business are growing at independent pharmacies. (3) The generic price war that was triggered by Wal-Mart is squeezing pharmacy margins on cash-pay consumers. While $4 generics may be good news for uninsured/underinsured patients, they are bad news for pharmacy owners.
-
An Unfortunate Victory for EU Repackagers
December 9, 2008
EU Exec Drops Drug Repackaging Ban Plan | www.reuters.com
Reuters reported on Friday that the EU plans to drop a proposed ban on repackaging of pharmaceuticals. In my opinion, dropping the ban is a very bad decision. Repackaging eliminates the benefit of just about every practical anti-counterfeit tracking technology, including the emerging serialization requirements in some EU countries. Apparently, tablets can even beremoved from blister packs under EU law. It’s hard to see how this will benefit consumers.
-
Cardinal Health Rebuilds Reputation with DEA Compliance Efforts
December 8, 2008
Cardinal Health Builds Out its 'Suspicious Order Monitoring Program' | pharmaceuticalcommerce.com
Now that Cardinal Health (CAH) has finally resolved its long-standing DEA issues, the company has quietly launched a series of intriguing Medication Safety web pages. I’m impressed by these initial public efforts at education and greater transparency, although it’s obviously a work-in-progress. Cardinal needs to more clearly describe how a more secure supply chain will translate into sales growth among its now highly monitored pharmacy customers. I’d also like to see the initiative evolve into anti-counterfeit education aimed at changing behavior by pharmacy buyers and consumers.
-
Pharmacy Groups Oppose First Databank AWP Settlement
December 3, 2008
NACDS and FMI filed another brief in opposition to the controversial proposed First Databank settlement, although they overstate their arguments in a few places. I expect this battle to heat up over the next month as we get closer to the late December hearing about First Databank’s settlement. This hearing represents another blow to the use of Average Wholesale Price (AWP) as a reimbursement benchmark for pharmaceuticals.
GLG Study Groups with Adam Fein(?)
GLG Live Meetings with Adam Fein(?)
Adam Fein has not participated in any GLG Live Meetings.